Skip to contentE
ENDRA Life Sciences Inc.
E
NDRAENDRA Life Sciences Inc. Q1 2021 · 10-Q
Revenue—
Net Income-$2.27M-$2.27MN/M vs Q1 2020 EPS Diluted-$0.06-$0.06N/M vs Q1 2020 Operating Income-$2,575,839N/M Operating Cash Flow-$2,923,483N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ENDRA Life Sciences Inc. · CIK 1681682 · Engraved from SEC EDGAR
Free Cash Flowderived-$2,968,483N/M ended Mar 31, 2021 · filed May 17, 2021 · 47 d after period end